The EMBARK Trial: Enzalutamide Plus ADT Achieves Unprecedented OS in nmCSPC | Targeted Oncology

Patients with nonmetastatic castration-sensitive prostate cancer (nmCSPC) who have high-risk biochemical recurrence have an increased risk of disease progression, including metastasis and mortality.¹ The phase 3 EMBARK trial (NCT02319837) sought…